CliffBio
small molecule

TEMOZOLOMIDE

TEMOZOLOMIDE

Loss of exclusivity—loss of exclusivity
CompanyEirGen Pharma →See this company's full patent-cliff portfolio

Drug detail

Brand nameTEMOZOLOMIDE
Active ingredientTEMOZOLOMIDE
Strength140MG
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalFebruary 2016
Marketing statusRX

More from EirGen Pharma

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

TEMOZOLOMIDE patent cliff — loss of exclusivity — | CliffBio